Author

William Kerrison

Institute of Cancer Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Aditi GulatiiD· 1 shared Andrew N.J. TuttiD· 1 shared Christopher J. LordiD· 1 shared Dragomir B. KrasteviD· 1 shared Éric Pujade-LauraineiD· 1 shared Feifei SongiD· 1 shared Hui Xiao· 1 shared Isabelle Laure Ray-CoquardiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aditi GulatiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Reversion mutations define minimal BRCA1/2 requirements for therapy resistance

Lorena Magraner-Pardo, William Kerrison, Dragomir B. Krastev, Rachel Alcraft, Hui Xiao, Rachel Brough, Feifei Song, Sheyne S. A. Choi, Aditi Gulati, Manuel Jorge Rodrigues, Sana Intidhar Labidi‐Galy, Éric Pujade-Lauraine, Isabelle Laure Ray-Coquard, Syed Haider, Stephen J. Pettitt, , Christopher J. Lord

The paper identifies BRCA1/2 reversion mutations associated with drug resistance in cancer patients and highlights key domains critical for resistance.

bioRxiv · May 25, 2026 · PreprintCancer Biology